drugset / Trial / NCT03084952
Phase 2 Trial to Evaluate 18-Methoxycoronaridine Efficacy, Safety and Tolerability in Cutaneous Leishmaniasis Patients
RandomizedSequentialOpen-labelTreatment
Summary
It is a randomized phase II clinical study, unicentre aimed to evaluate the tolerability, safety and efficacy of 18-Methoxyoronaridine as a candidate of tegumentary leishmaniasis treatment.
Timeline
- Start
- 2021-05
- Primary completion
- 2023-12
- Completion
- 2024-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 18-Methoxycoronaridine | Unknown | 1 mg | — |
| Subject | 18-Methoxycoronaridine | Unknown | 4 mg | — |
| Subject | 18-Methoxycoronaridine | Unknown | 8 mg | — |
| Subject | 18-Methoxycoronaridine | Unknown | 12 mg | — |
| Comparator | Meglumine antimonate | Other / unclassified | — | — |